Abstract
We have studied serological and clinical response to live, attenuated varicella zoster virus (VZV) vaccine (Varilrix, SmithKline Beecham) in 20 patients with steroid-sensitive nephrotic syndrome (SSNS) in remission and 22 normal controls who had no history of varicella and no detectable antibody to VZV. Nephrotic patients included 15 boys and 5 girls, with a mean age of 4.7 years (range 2–11.4 years). The controls were healthy age-matched children (13 girls and 9 boys). Seventeen patients with SSNS (85%) and 19 healthy controls (86%) seroconverted 8 weeks after vaccination. One patient with SSNS had a relapse 20 days after vaccination, and 1 child in the control group had a rash. Two years after vaccination, antibodies to VZV were detected in 12 of 17 responders, 2 of 3 non-responders, and 13 of 22 controls. Within 2 years of vaccination, 3 of the vaccine responder children with SSNS had a mild varicella infection. Two responder and 1 non-responder nephrotic children and 9 controls were lost to long-term follow-up. Our results show that immunization with a single dose of VZV vaccine is safe and effective in children with SSNS in remission.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 9 May 2001 / Revised: 15 November 2001 / Accepted: 18 November 2001
Rights and permissions
About this article
Cite this article
Alpay, H., Yıldız, N., Onar, A. et al. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 17, 181–183 (2002). https://doi.org/10.1007/s00467-001-0789-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-001-0789-7